Alivira Animal Health USA LLC Balance Sheet as at 31 March 2022 Amounts in USD (\$) unless otherwise stated

A ASSETS	Notes	As at 31 March 22	As at 31 March 21
1 Non-current assets			
2 Current assets			
(i) Cash and cash equivalents Total current assets	3	6,972	23,690
I otal current assets		6,972	23,690
TOTAL ASSETS			
TOTAL ASSETS		6,972	23,690
B EQUITY AND LIABILITIES			
1 Equity (a) Equity share capital (b) Other Equity Retained Earnings Total equity	4 5	597,500 (704,972) (107,472)	288,000 (295,560) (7,560)
2 Non-Current Liabilities			
3 Current liabilities (a) Financial Liabilities			
(i) Trade payables	6	110,311	31,250
(b) Other current liabilities	7	4,133	0
Total		114,444	31,250
TOTAL FOURTY AND LINE			
TOTAL EQUITY AND LIABILITIES		6,972	23,690
s per our report of quant data			

As per our report of event date For M O J & ASSOCIATES Chartered Accountants ICAI FRN: 015425S

& ASSC

Avneep L Mehta Partner

Membership no. 225441

Date: 23 May 2022 Place: Banglore Alan Kelly Authorised Signatory Vice President

Alivira Animal Health USA LLC
Statement of Profit and Loss for year ended 31 March 2022
Amounts in USD (\$) unless otherwise stated

	Particulars	Notes	Year ended 31 March 2022	Year ended 31 March 2021
(I)	Total Income (I)		-	-
(II)	EXPENSES Employee benefits expense Finance costs Other expenses Total expenses (II)	8 9 10	679,589 - 2,340 681,929	293,966 90 1,504 295,560
(III)	Profit before tax (I- II)		(681,929)	(295,560)

As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

Avneep L Mehta

Partner

Membership no. 225441

Date: 23 May 2022 Place: Banglore Alan Kelly Authorised Signatory

Vice President

Alivira Animal Health USA LLC Statement of cash flows for the year ended 31 March 2022 Amounts in USD (\$) unless otherwise stated

Particulars		Year ended 31 March 2022	Year ended
Cash flow from operating activities		31 Warch 2022	31 March 2021
Net Profit before tax Adjustments for:		(681,929)	(295,560)
Share based payment to employees Finance cost		272,517	00
Operating profit before working capital changes		(409,412)	90
and anticon all miles		(403,412)	(295,470)
Changes in working capital			
Increase/(decrease) in trade and other payables		83,194	31,250
Net change in working capital		83,194	31,250
Cash generated from/ (used in) operations		(326,218)	(264,220)
Direct taxes (paid)/refund		(,/	(201,220)
Net cash generated from/ (used in) operations	A	(326,218)	(264,220)
Net cash generated from investing activities	В		-
Cash flow from financing activities			
Proceeds from Share capital		309,500	288,000
Interest Cost		000,000	(90)
Net cash generated from financing activities	c	309,500	287,910
Net increase/(decrease) In cash and cash equivalents during the year/ period	(A+B+C)		
sie year periou		(16,718)	23,690
Cash and cash equivalents at the beginning of the year (refernote 3)		23,690	
Cash and cash equivalents at the end of the year	_	6,972	23,690
Significant Accounting Policies	2		

The accompanying notes are an integral part of the financial statements. As per our report of event date For M O J & ASSOCIATES Chartered Accountants ICAI FRN: 015425S

ASSOC

Avneep L Mehta

Partner

Membership no. 225441

Date: 23 May 2022 Place: Banglore

Alan Kelly **Authorised Signatory**

Vice President

Alivira Animal Health USA LLC
Notes forming part of the financial statements for the year ended 31 March, 2022

Note

1 Corporate Information

The Company incorporated on 25 March 2020, is a private company limited by shares. The company seeks to develop, manufacture and sell veterinary products, including both active pharmaceutical ingredients (API) and formulations to cater to the global market.

2 Significant accounting policies

2.1 Basis of accounting and preparation of financial statements

The Financial Statements have been prepared on accrual basis under the historical cost convention.

The financial statements of Alivira Animal Health limited ('the Company') have been prepared, in accordance with Indian Accounting Standards ('Indian Accounting Standards) Rules, 2015.

2.2 Functional and Presentation Currency

These financial statements are presented in US Dollars ("\$") which is the Company's functional currency. The Directors of the Company believe that \$ most faithfully represents the economic effects of the underlying transactions, events and conditions.

2.3 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

2.4 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Dituted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.

2.5 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

2.6 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2.7 Segment

Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the

2.8 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of and financing activities are segregated based on the available information.

2.9 Cash and cash equivalents (for purposes of cash flow statement)

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

2.10 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash and non-current.



fll)

Alivira Animal Health USA LLC Statement of Changes in Equity (SOCIE) for the year ended 31 March 2022

Amounts in USD (\$) unless otherwise stated

(a) Equity share capital	As at 31 March, 2	022	As at 31 March, 2	021
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting year	288,000	288,000		
Issued During the year	309,500	309.500	288,000	200 000
Balance at the end of the reporting year	597,500	597,500	288,000	288,000 288,000

(b) Other Equity

Particulars	Reserves at	Total	
	Share option Outstanding account	Retained Earnings	
Balance at March 31, 2021	-	(295,560)	(295,560)
Movement during the year	272,517		272,517
Loss for the year	-	(681,929)	(681,929)
Balance at March 31, 2022	272,517	(977,489)	(704,972)

The accompanying notes are an integral part of the financial statements.

As per our report of event date For M O J & ASSOCIATES Chartered Accountants ICAI FRN: 015425S

Avneep L Mehta Partner Membership no. 225441

Date: 23 May 2022 Place: Banglore

Alan Kelly Authorised Signatory Vice President

Alivira Animal Health USA LLC Notes to the financial statements for year ended 31 March 2022 Amounts in USD (5) unless otherwise stated

te no							As at	As at
3	Cash and cash equivalents						31 Mar 2022	31 March 2021
	Balances with banks							
	- In current accounts		1				6.972	00.00
	Total		1				6,972	23,69
							0,512	23,65
4	Share capital						As at 31 Mar 2022	As at 31 March 2021
	Equity share capital						597,500	
	Total					19	597,500	288,00 288,00
5	Other Equity						As at 31 Mar 2022	As at 31 March 2021
	Retained Earnings						(295,560)	
	Loss for the year						(681,929)	(295,566
							(977,489)	(295,560
	II) Other Reserves							
	Share Options Outstanding Account						272,517	
	Total		1				272,517	
							-704,972	(295,560
5	Trade payable						As at 31 Mar 2022	As at 31 March 2021
	Trade payable		1				110,311	
	Total					-	110,311	31,250
	As on 31 March 2022					•		31,230
ſ			Ou	standing for	following	periods	from due date of p	tyment
	Particulars Tendo Countries	Unbil		Not due	1-2 years	2-3 years	More than 3 years	Total
	Trade Payables Total			110,311				110.311
L	10(8)		+ 1	110,311				110,311
4	As on 31 March 2021							
			Ou	tstanding for	following	periods	from due date of pa	yment
	Particulars	Unbill		Not due	1-2 years	2-3 years	More than 3 years	Total
	Trade Payables			31,250		1	o years	31,250
	l'otal			31.250				

7 Other current liabilities Statutory remittances Other current liabilities

& ASSOCI

As at 31 Mar 2022 31 March 2021 4,133 0 4,133 0



Alivira Animal Health USA LLC Notes to the financial statements for year ended 31 March 2022 Amounts in USD (\$) unless otherwise stated

Note no

0	Employee benefits expense	1
	Salaries and wages	
	Contribution to provident and	other funds
	Expense on employee stock i	ased compensation*
	Staff welfare expenses	

9	Finance	
	rmance	COSIS

Total

Other borrowing costs Total

10 Other expenses

Legal and Professional charges Rates and taxes Total



Year ended	Year ended
31 March 2022	31 March 2021
379,610	275,762
	-
272,517	-
27,462	18,204
679,589	293,966
Year ended	Year ended
31 March 2022	31 March 2021
-	90
	90
Year ended	Year ended
31 March 2022	31 March 2021
1,339	1,504
1,001	-
2,340	1,504



Alivira Animal Health USA LLC
Notes to the financial statements for year ended 31 March 2022
Amounts in USD (\$) unless otherwise stated

11 Control of the Company

Sequent Scientific Limited is the ultimate controlling Company, which is incorporated and domiciled in India.

12 Contingent liabilities and commitments

There are no contingent liability and commitments

13 Segment information

Segments have been identified laking into account the nature of services, the differing risks and returns, the organisational structure and the internal reporting system

Primary segment: Business segment

The Company is mainly engaged in the business of trading and marketing of Pharmaceutical products. Considering the nature of business and financial reporting of the Company, the Company has only one business segment viz; Pharmaceuticals as primary reportable segment. All the activies of the Company are in USA.

As per our report of event date

For M O J & ASSOCIATES Chartered Accountants

ICAI FRN: 015425S

Avneep L Mebra

Partner

Membership no. 225441

Date: 23 May 2022 Place: Banglore Alan Kelly

Authorised Signatory

Vice President